Recommendations for future reading

Incidence of and risk factors for sudden cardiac death in children with dilated cardiomyopathy: a report from the Pediatric Cardiomyopathy Registry. Authors: Pahl E. Sleeper LA. Canter CE. Hsu DT. Lu M. Webber SA. Colan SD. Kantor PF. Everitt MD. Towbin JA. Jefferies JL. Kaufman BD. Wilkinson JD. Lipshultz SE. Pediatric Cardiomyopathy Registry Investigators. Journal of the American College of Cardiology. 59(6):607-15, 2012 Feb 7.

Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and achocardiography.  Authors: Leong DP. Chakrabarty A. Shipp N. Molaee P. Madsen PL. Joerg L. Sullivan T. Worthley SG. De Pasquale CG. Sanders P. Selvanayagam JB.
European Heart Journal. 33(5):640-8, 2012 Mar.

Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease.
Authors: Namdar M. Steffel J. Jetzer S. Schmied C. Hurlimann D. Camici GG. Bayrak F. Ricciardi D. Rao JY. de Asmundis C. Chierchia GB. Sarkozy A. Luscher TF. Jenni R. Duru F. Brugada P.
American Journal of Cardiology. 109(4):587-93, 2012 Feb 15.

Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy.
Authors: Appelbaum E. Maron BJ. Adabag S. Hauser TH. Lesser JR. Haas TS. Riley AB. Harrigan CJ. Delling FN. Udelson JE. Gibson CM. Manning WJ. Maron MS.
Circulation. Cardiovascular imaging. 5(1):78-85, 2012 Jan.

The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy.
Authors: O'Mahony C. Lambiase PD. Quarta G. Cardona M. Calcagnino M. Tsovolas K. Al-Shaikh S. Rahman SM. Arnous S. Jones S. McKenna W. Elliott P.
Heart. 98(2):116-25, 2012 Jan

 A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy.
Authors: Ingles J. McGaughran J. Scuffham PA. Atherton J. Semsarian C.
Heart. 98(8):625-30, 2012 Apr.

Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome.
Authors: Page SP. Kounas S. Syrris P. Christiansen M. Frank-Hansen R. Andersen PS. Elliott PM. McKenna WJ. Circulation. Cardiovascular Genetics. 5(2):156-66, 2012 Apr 1

Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Authors: Maron MS. Journal of Cardiovascular Magnetic Resonance. 14:13, 2012.

Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin gene.  Authors: Pasquale F. Syrris P. Kaski JP. Mogensen J. McKenna WJ. Elliott P. Circ Cardiovasc Genet. 2012 Feb 1;5(1):10-7. Epub 2011 Dec 5.

Novel desmoplakin mutation: juvenile biventricular cardiomyopathy with left ventricular non-compaction and acantholytic palmoplantar keratoderma. Authors: Williams T, Machann W, Kuhler L, Hamm H, Muller-Hocker J, Zimmeri M, Ertl G, Ritter O, Beer M, Schonberger J. Clinical Research in Cardiology. 2011;100(12):1087-93.

Utility of Doppler tissue imaging-derived indices in identifying subclinical systolic ventricular dysfunction in children with restrictive kardiomyopathy. Authors: Sasaki N, Garcia M, Lytrivi I, Ko H, Nielsen J, Parness I, Srivastava S. Pediatric Cardiology. 2011;32(5):646-51.

Constrictive pericarditis and restrictive cardiomyopathy in the modern era. Authors: Mookadam F, Jiamsripong P, Raslan SF, Panse PM, Tajik AJ. Future Cardiology. 2011;7(4):471-483.

Diagnostic Work-Up and Risk Stratification in X-Linked Dilated Cardiomyopathies Caused by Dystrophin Defects. Authors: Diegoli M, Grasso M, Favalli V, Serio A, Gambarin F I, Klersy C, Pasotti M, Agozzino E, Scelsi L, Ferlini A, Febo O, Piccolo G, Tavazzi L, Narula J, Arbustini E.J Am Coll Cardiol. 2011;58(9):925-34.

A rare case of Epstein-Barr virus-induced dilated cardiomyopathy. Authors: Mutlu H, Alam M, Ozbilgin OF.Heart&Lung. 2011;40(1);81-7.

Usefulness of heart rate turbulance for predicting cardiac events in patients with nonischemic dilated cardiomyopathy. Authors: Ikeda T, Miwa Y, Abe A, Nakazawa K. Journal of Electrocardiology. 2011;44(6):669-72.

Placental Growth Factor Regulates Cardiac Inflammation Through the Tissue Inhibitor of Metalloproteinases-3/Tumor Necrosis Factor-α–Converting Enzyme Axis: Crucial Role for Adaptive Cardiac Remodeling During Cardiac Pressure Overload. Authors : Carnevale D, Cifelli G, Mascio G, Madonna M, Sbroggió M, Perrino C, Persico MG, Frati G, Lembo G. Circulation. 2011;124(12):1337-50.

Reciprocal Transcriptional Regulation of Metabolic and Signaling Pathways Correlates With Disease Severity in Heart Failure. Authors: Barth A, Kumordzie A, Frangakis C, Margulies KB, Cappola TP, Tomaselli G. Circulation Cardiovascular Genetics. 2011;4:469-71.

Basic Science for Clinicians. Phenotyping Patient-Derived Cells for Translational Studies in Cardiovascular Disease. Authors: Shae S, Brettman A. Circulation. 2011;124:2444-55.

Images in Cardiovascular Medicine: Recurrent Stress Cardiomyopathy With Variable Regional Involvement. Authors: Kaushik M, Alla VM, Madan R, Arouni AJ, Mohiuddin SM.Circulation. 2011;124:e556-7.

Diagnostic work-up and risk stratification in X-linked dilated cardiomyopathies caused by dystrophin defects.
Authors:Diegoli M, Grasso M, Favalli V, Serio A, Gambarin Fl, Klersy C, Pasotti M, Agozzin0 E, Scelsi L, Ferlini A, Febo O, Piccolo G, Tavazzi L, Narula J, Arbustini E.  Journal of the  American College of Cardiology. 2011; 58(9):925-34.

Association of diabetes mellitus with myocardila collagen accumulation and relaxation impairment in patients with dilated cardiomyopathy. Authors:Sakakibara M, Hirashiki A, Cheng XW, Bando Y, Ohshima K, Okumura T, Funahashi H, Ohshima S, Murohara T.  Diabetes Research & Clinical Practice. 2011;92(3): 348-55.

Restrictive cardiomyopathy as a cardiac manifestation of myofibrillar myopathy.
Authors: Finsterer J, Stollberger C, Hoftberger R.  Heart & Lung. 2011;40:(5):e123-7.

Furthering the link between the sarcomere and primary cardiomyopathies: restrictive cardiomyopathy associated with multiple mutations in genes previously associated with hypertrophic or dilated cardiomyopathy.
Authors: Caleshu C, Sakhuja R, Nussbaum RL, Schiller NB, Ursell PC, Eng C, De Marco T, McGlothlin D, Burchard EG, Rame JE.  American Journal of Medical Genetics. 2011; 155A(9):2229-35.

Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.
Authors: Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, Dalal D, Tedford R, Russell SD, Abraham T, Tandri H, Judge DP, Calkins H.  Journal of the American College of Cardiology. 2011;58(14):1485-96.

Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy –overlap syndromes.
Authors: Taylor M, Graw S, Sinagra G, Barnes C, Slavov D, Brun F, Pinamonti B, Salcedo EE, Sauer W, Pyxaras S, Anderson B, Simon B, Bogomolovas J, Labeit S, Granzier H, Mestroni L.  Circulation. 2011;124(8):876-85.

Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management.
Authors: Elkayam U. - Journal of the American College of Cardiology. 2011;58:(7):659-70.

Chemical cardiomyopathies: the negative effects of medications and nonprescribed drugs on the heart.
Authors: Figueredo VM.  - American Journal of Medicine. 2011;124(6):480-8.

Positron emission tomography for the evaluation and treatment of cardiomyopathy.
Authors: Shah P, Choi BG, Mazhari R. - Annals of the New York Academy of Sciences. 2011; 1228:137-49.

The ubiquitin-proteasome system in cardiomyopathies
Authors: Schlossarek K, Carrier L.  Current Opinion in Cardiology.2011;26(3):190-5.

Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation
Authors: Sipola P, Magga J, Husso M, Jääskeläinen P, Peuhkurinen K, Kuusisto J.  European Radiology.2011;21(7):1383-9.

Exome sequencing identifies mitochondrial alanyl-tRNA-synthetase mutations in infantile mitochondrial cardiomyopathy.
Authors: Götz A, Tyynismaa H, Euro L, Ellonen P, Hyötyläinen T, Ojala T, Hämäläinen RH,Tommiska J, Raivio T, Oresic M, Karikoski R, Tammela O, Simola KO, Paetau A, Tyni T.  American Journal of Human Genetics.2011;88(5):635-42.

Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carrieirs: determining the best cardiological screening strategy.
Authors: Christiaans I, Birnie E, Bosnel GJ, Mannens MM, Michels M, Majoo-Krakauer D, Dooijes D, van Tintelen JP, van den Berg MP, Volders PG, Arens YH, van den Wijngaard A, Atsma DE, Helderman-van den Enden AT, Houweling AC, de Boer K, van der Smagt JJ,Hauer RN, Marcelis CL, Timmermans J, van Langen IM, Wilde AA.  European Heart Journal.2011;32(9):1161-70.

Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy.
Authors: Monserrat L, Lopez B, Gonzalez A, Hermida M, Fernandez X, Ortiz M, Barriales-Villa R, Castro-Beiras A, Diez J.  European Heart Journal. 2011;32(2):177-83.

Signaling and myosin –binding protein C.
Authors: James J, Robbins J. Review Journal of Biological Chemistry. 2011;286(12):9913-9.

A mutation in C2orf64 causes impaired cytochrome c oxidase assembly and mitochondrial cardiomyopathy.
Authors: Huigsloot M, Nijtmans LG, Szklarczyk R, Baars MJ, van den Brand MA, Hendriksfranssen MG, van den Heuvel LP, Smeitink JA, Huynen MA, Rodenburg RJ.   American Journal of Human Genetics.2011;88(4):488-93.

Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised force criteria.
Authors: Quarta G, Muir A, Pantazis A, Syris P, Gehmlich K, Garcia-Pavia P, Ward D, Sen-Chowdhry S, Elliott P, McKenna WJ. Circulation. 2011;123(23):2701-9.

Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia –associated mutations from background genetic noise.
Authors: Kapplinger JD, Landstrom AP, Salisbury BA, Callis TE, Pollevick GD, Tester DJ, COX MG, Bhuiyan Z, Bikker H, Wisfeld AC, Hauer RN, van Tintelen JP, Jongbloes JD, Calkins H, Judge DP, Wilde AA, Ackerman MJ.  Journal of the American College of Cardiology. 2011;57(23):2317-27.

Arrhythmogenic right ventricular cardiomyopathy/dysplasia on the basis of the revised diagnostic criteria in affected families with desmosomal mutations.
Authors: Protonotarios N, Anastasakis A, Antoniades L, Chlouverakis G, Syrris P, Basso C, Asimaki A, Thepistou A, Stefanidis C, Thiene G, McKenna WJ, Tsatsopoulou A.  European Heart Journal.2011;32(9):1097-104.

• Reader- and instrument-dependent variability in the electrocardiographic assessment of arrhythmogenic right ventricular dysplasia / cardiomyopathy.
  Authors: Jain R, Tandri H, Daly A, Tichnell C, James C, Abraham T, Judge DP, Calkins H, Dalal D.  J Cardiovasc Electrophysiol. 2011 May;22(5):561-8 

• Natural history of Danon disease.
  Authors: Boucek D, Jirikowic J, Taylor M.  Genetics in Medicine 13(6):563-8, 2011.

• Relation of ventricular tachycardia/fibrillation to Beta-blocker dose maximization guided by pacing mode analysis in nonpacemaker-dependent patients with implantable cardioverter-defibrillator.
  Authors: Deftereos S, Giannopoulos G, Kossyvakis C, Kaoukis A, Raisakis K, Panagopoulou V, Ntzouvara O, Perpinia A, Rentoukas I, Pyrgakis V, Manolis AS, Stefanidis C. American Journal of Cardiology. 107(12):1812-7.2011.

• Targeted next-generation sequencing for the molecular genetic diagnostics in cardiomyopathies
  Authors: Meder B, Haas J, Keller A, Heid C, Just S, Borries A, Boisguerin V, Scharfenberger-Schmeer M, Stahler P, Beier M, Weichenhan D, Strom TM, Pfeufer A, Korn B, Katus HA, Rottbauer W.  Circulation. Cardiovascular Genetics. 4(2):110-22,2011.

• Genetics of sudden cardiac death syndromes.
  Authors: Chopra N, Knollman BC.  Current Opinion in Cardiology.26(3):196-203,2011.

• Cardiac magnetic resonance imaging in dilated cardiomyopathy in adults-towards identification of myocardial inflammation.
  Authors: Voigt A, Elgeti T, Durmus T, Ece M, Butler , Beling M, Schilling R, Klingel K, Kandolf R, Stangl K, Taupitz M, Kivelitz D, Wagner M. European Radiology. 21(5):925-35,2011.

• Arrhythmias and dilated cardiomyopathy common pathogenetic pathways?
  Authors: Towbin JA, Lorts A. Journal of the American College of Cardiology.57(2):2169-71, 2011.

• Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy.
  Authors: Lombardi AD, Rodriguez G, Mitchell MM, Marian AJ. European Journal of Clinical Investigation. 41(5):527-38, 2011.

• Coming from the past: Tuberculous chronic constrictive pericarditis.
  Authors:Caroselli C, Manara F, Bruno G. American Journal of the Medical Sciences. 2011;341:233.

• TRIF is a critical survival factor in viral cardiomyopathy. Authors: Riad A, Westermann D, Zietsch C, Savvatis K, Becher PM, Bereswill S, Heimesaat MM, Lettau O, Lassner D, Dorner A, Poller W, Busch M, Felix SB, Schultheiss HP, Tschope C. Journal of Immunology. 2011;186:2561-70.

• Up-regulation  of ectopic trypsins in the myocardium by influenza A virus infection triggers acute myocarditis.
  Authors: Pan HY, Yamada H, Chida J, Wang S, Yano M, Yao M, Zhu J, Kido H. Cardiovascular Research. 2011;89:595-603.

• Telmisartan ameliorates experimental autoimmune myocarditis associated with inhibition of inflammation and oxidative stress.
  Authors:Sukumaran V, Watanabe K, Veeraveedu PT, Ma M, Gurusamy N, Rajavel V, Suzuki K, Yamaguchi K, Kodama M, Aizawa Y. European Journal of Pharmacology. 2011;652:126-35.

• Inherited cardiomyopathies.
  Authors:Watkins H, Ashrafian H, Redwood C.  New England Journal of Medicine. 2011;364:1643-56.

• RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it.
  Authors:Gelb BD, Tartaglia M.  Journal of Clinical Investigation. 2011;121:844-7.

• Reverse electrophysiologic remodeling after cardiac mechanical unloading for end-stage nonischemic cardiomypathy.
  Authors:Drakos SG, Terrovitis JV, Nanas JN, Charitos EI, Ntalianis AS, Malliaras KG, Diakos N, Koudoumas D, Theodoropoulos S, Yacoub MH, Anastasiou-Nana MI.  Annals of Thoracic Surgery. 2011;91:764-9.

• Increased inflammatory response in patients with dilated cardiomyopathy is associated with dyslipidemia: Effects of statin therapy.
  Authors: Lakovis P, Anyfantakis ZA, Limas C, Kroupis C, Degiannis D, Cokkinos DV.Angiology. 2011;62:55-61.

• Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase.
  Authors: A Ha KN. Masterson LR. Hou Z. Verardi R. Walsh N. Veglia G. Robia SL. Proceedings of the National Academy of Sciences of the USA. 108(7):2735-40, 2011 Feb 15

• The ShcA phosphotyrosine docking protein uses distinct mechanisms to regulate myocyte and global heart function
  .Authors: Vanderlaan RD. Hardy WR. Kabir MG. Pasculescu A. Jones N. deTombe PP. Backx PH. Pawson T. Circulation Research. 108(2):184-93, 2011 Jan 21.

• Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy
  . Authors: Nodari S. Triggiani M. Campia U. Manerba A. Milesi G. Cesana BM. Gheorghiade M. Dei Cas L. Journal of the American College of Cardiology. 57(7):870-9, 2011 Feb 15.

• Effects of cardiac resynchronisation therapy on dilated cardiomyopathy with isolated ventricular non-compaction
  . Authors: Bertini M. Ziacchi M. Biffi M. Biagini E. Rocchi G. Martignani C. Ferlito M. Pasquale F. Cervi E. Branzi A. Rapezzi C. Boriani G. Heart. 97(4):295-300, 2011 Feb.

• Adiponectin is associated with abnormal lipid profile and coronary microvascular dysfunction in patients with dilated cardiomyopathy without overt heart failure. Authors: Giannessi D. Caselli C. Del Ry S. Maltinti M. Pardini S. Turchi S. Cabiati M. Sampietro T. Abraham N. L'abbate A. Neglia D. Metabolism: Clinical & Experimental. 60(2):227-33, 2011 Feb

• Increased inflammatory response in patients with dilated cardiomyopathy is associated with dyslipidemia: Effects of statin therapy.
  Authors: Iakovis P. Anyfantakis ZA. Limas C. Kroupis C. Degiannis D. Cokkinos DV. Angiology. 62(1):55-61, 2011 Jan.

• Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity.
  Authors: Joshi S. Patel UK. Yao SS. Castenada V. Isambert A. Winson G. Chaudhry FA. Sherrid MV. Journal of the American Society of Echocardiography. 24(1):75-82, 2011 Jan.

• Increased left ventricular torsion in hypertrophic cardiomyopathy mutation carriers with normal wall thickness.
  Authors: Russel IK. Brouwer WP. Germans T. Knaapen P. Marcus JT. van der Velden J. Gotte MJ. van Rossum AC.  Journal of Cardiovascular Magnetic Resonance. 13:3, 2011.

• Calcineurin Protects the Heart in a Murine Model of Dilated Cardiomyopathy.
  Authors: Heineke J, Wollert KC, Osinska H, Sargent MA, York AJ, Robbins J, Molkentin JD J Mol Cell Cardiol. 2009 Oct 22. [Epub ahead of print

• Myocardin is required for cardiomyocyte survival and maintenance of heart function.
  Authors: Huang J, Lu MM, Cheng L, Yuan LJ, Zhu X, Stout AL, Chen M, Li J, Parmacek MS. Proc Natl Acad Sci U S A. 2009 Oct 22. [Epub ahead of print]

• New ECG criteria in arrhythmogenic right ventricular dysplasia/cardiomyopathy.
  Authors: Cox MG, van der Smagt JJ, Wilde AA, Wiesfeld AC, Atsma DE, Nelen MR, Rodriguez LM, Loh P, Cramer MJ, Doevendans PA, van Tintelen JP, de Bakker JM, Hauer RN. Circ Arrhythm Electrophysiol. 2009 Oct;2(5):524-30. Epub 2009 Jul 7.

• Myocarditis: Infection Versus Autoimmunity.
  Rose NR .J Clin Immunol. 2009 Oct 14. [Epub ahead of print]

• Immunological aspect of cardiac remodeling: T lymphocyte subsets in inflammation-mediated cardiac fibrosis.
  Authors: Wei L. Experimental & Molecular Pathology. 2011;90:74-8.

• Acute myocarditis mimicking reverse Takotsubo cardiomyopathy.
  Authors: Karamitsos TD, Bull S, Ferreira V, Alp NJ, Neubauer S. Circulation. 2011;123:226-7. .

• Gene therapy with CCL2 (MCP-1) mutant protects CVB3-induced myocarditis by compromising Th1 polarization.
  Authors: Yue Y, Gui J, Xu W, Xiong S. Molecular Immunology. 2011;48:706-13.

• A small pericardial effusion is a marker of increased mortality.
  Authors: Mitiku TY, Heidenreich PA. American Heart Journal. 2011;161:152-7.

• Cardiac and skeletal muscle defects in a mouse model of human Barth syndrome.
  Authors: Acehan DVF, Houtkooper RH, Moore JJ, Tokunaga C, Kulik W, Wansapura J, Toth MJ, Strauss A, Khuchua Z. Journal of Biological Chemistry. 2011;286; 899-908.

• Focus study investigators. Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study.
  Authors: Hagège AA, Caudron E, Damy T, Roudaut R, Millaire A, Etchecopar-Chevreuil C, Tran TC, Jabbour F, Boucly C, Prognon P, Charron P, GermaIn DP, Heart. 2011;97:131-6.

• PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the litterature and implications for genetic testing.
  Authors: Landstrom AP, Adekola BA, Bos JM, Ommen SR, Ackerman MJ. American Heart Journal. 2011;161:165-71.

• Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase A
  Authors: Ha KN. Masterson LR. Hou Z. Verardi R. Walsh N. Veglia G. Robia SL. Proceedings of the National Academy of Sciences of the USA. 108(7):2735-40, 2011 Feb 15

• The ShcA phosphotyrosine docking protein uses distinct mechanisms to regulate myocyte and global heart function.
  Authors:Vanderlaan RD. Hardy WR. Kabir MG. Pasculescu A. Jones N. deTombe PP. Backx PH. Pawson T. Circulation Research. 108(2):184-93, 2011 Jan 21.

• Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy
  Authors: Nodari S. Triggiani M. Campia U. Manerba A. Milesi G. Cesana BM. Gheorghiade M. Dei Cas L. Journal of the American College of Cardiology. 57(7):870-9, 2011 Feb 15.

• Effects of cardiac resynchronisation therapy on dilated cardiomyopathy with isolated ventricular non-compaction.
  Authors: Bertini M. Ziacchi M. Biffi M. Biagini E. Rocchi G. Martignani C. Ferlito M. Pasquale F. Cervi E. Branzi A. Rapezzi C. Boriani G. Heart. 97(4):295-300, 2011 Feb.

• Adiponectin is associated with abnormal lipid profile and coronary microvascular dysfunction in patients with dilated cardiomyopathy without overt heart failure.
  Authors: Giannessi D. Caselli C. Del Ry S. Maltinti M. Pardini S. Turchi S. Cabiati M. Sampietro T. Abraham N. L'abbate A. Neglia D. Metabolism: Clinical & Experimental. 60(2):227-33, 2011 Feb

• Increased inflammatory response in patients with dilated cardiomyopathy is associated with dyslipidemia: Effects of statin therapy.
  Authors: Iakovis P. Anyfantakis ZA. Limas C. Kroupis C. Degiannis D. Cokkinos DV. Angiology. 62(1):55-61, 2011 Jan.

• Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity.
  Authors: Joshi S. Patel UK. Yao SS. Castenada V. Isambert A. Winson G. Chaudhry FA. Sherrid MV. Journal of the American Society of Echocardiography. 24(1):75-82, 2011 Jan.

• Increased left ventricular torsion in hypertrophic cardiomyopathy mutation carriers with normal wall thickness
  Authors: Russel IK. Brouwer WP. Germans T. Knaapen P. Marcus JT. van der Velden J. Gotte MJ. van Rossum AC.  Journal of Cardiovascular Magnetic Resonance. 13:3, 2011.